SCHEMBL6016797

SCHEMBL6016797

CC(C)(C)OC(=O)N1C(=O)C2CCCCC2C1(C)C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.36
ATM Q13315 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
HPGD P15428 1/20 0.35
DDB1 Q16531 2/20 0.33
CRBN Q96SW2 2/20 0.33
PDE4B Q07343 2/20 0.33
BUB1 O43683 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PREP P48147 1/20 0.32
ELANE P08246 1/20 0.32
GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19217730 0.70 EPHX1 (0.46) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL19217727 0.70 EPHX1 (0.46) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL17007375 0.70 DDB1 (0.36) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL14635333 0.69 BUB1 (0.33) CHRM2CHRM1CHRM3DDB1CRBN
SCHEMBL12565056 0.68 EPHX1 (0.40) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL13253756 0.68 EPHX1 (0.40) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL3735766 0.68 LIPE (0.39) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL22034964 0.67 PDE4A (0.46) EPHX1HPGDPDE4BKDM4EMAPT
SCHEMBL6016830 0.67 EPHX1 (0.37) EPHX1CHRM2CHRM1CHRM3HPGD
SCHEMBL33525666 0.66 CHRM2 (0.35) EPHX1CHRM2CHRM1CHRM3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615886-A1 [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS Warner-Lambert Company LLC (US) 2006-01-18 EP disclosed
US-20050137215-A1 [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions GUZZO PETER R (US) 2005-06-23 US disclosed
WO-2004092134-A1 [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS WARNER-LAMBERT COMPANY LLC (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137215-A1 [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions PPIC, PRAP1, PRRC2C EPHX1 3654/4885ATM 3966/4885CHRM2 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.